These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients. Barroso-García N; Atienza-Mateo B; Ferraz-Amaro I; Prieto-Peña D; Beltrán E; Adán A; Hernández-Garfella M; Martínez-Costa L; Cordero-Coma M; Díaz-Llopis M; Herreras JM; Maíz-Alonso O; Torre-Salaberri I; De Vicente-Delmás A; Díaz-Valle D; Atanes-Sandoval A; Francisco F; Insua S; Sánchez J; Almodóvar-González R; Jiménez-Sosa A; Ruiz-Moreno O; Gandía-Martínez M; Nolla JM; Calvo-Río V; Castañeda S; González-Gay MA; Blanco R Semin Arthritis Rheum; 2023 Feb; 58():152153. PubMed ID: 36549244 [TBL] [Abstract][Full Text] [Related]
5. Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study. Takeuchi M; Usui Y; Namba K; Keino H; Takeuchi M; Takase H; Kamoi K; Hase K; Ito T; Nakai K; Maruyama K; Kobayashi E; Mashimo H; Sato T; Ohguro N; Hori J; Okada AA; Sonoda KH; Mizuki N; Goto H Front Med (Lausanne); 2023; 10():1095423. PubMed ID: 36744150 [TBL] [Abstract][Full Text] [Related]
6. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients. Maalouf G; Andrillon A; Leclercq M; Sève P; Bielefeld P; Gueudry J; Sené T; Titah C; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; Thibault T; Chamieh CE; Cacoub P; Kodjikian L; Biard L; Bodaghi B; Saadoun D Am J Ophthalmol; 2022 Jun; 238():173-180. PubMed ID: 35172172 [TBL] [Abstract][Full Text] [Related]
7. Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis. Mase O; Qasem M; Beare N BMJ Open Ophthalmol; 2023 Jun; 8(1):. PubMed ID: 37493653 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study. Esatoglu SN; Akkoc-Mustafayev FN; Ozguler Y; Ozbakır F; Nohut OK; Cevirgen D; Hamuryudan V; Hatemi I; Celik AF; Yazici H; Hatemi G Front Immunol; 2020; 11():618973. PubMed ID: 33414791 [TBL] [Abstract][Full Text] [Related]
10. Tocilizumab in Behçet Disease: A Multicenter Study of 30 Patients. Khitri MY; Bartoli A; Maalouf G; Deroux A; Salvarani C; Emmi G; Karadag O; Espinosa G; Leclercq M; Simonini G; Vautier M; Cacoub P; Saadoun D J Rheumatol; 2023 Jul; 50(7):916-923. PubMed ID: 36858435 [TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis. Ucar D; Esatoglu SN; Cerme E; Batu-Oto B; Hamuryudan V; Seyahi E; Melikoglu M; Fresko I; Ozyazgan Y; Hatemi G Rheumatol Int; 2023 Nov; 43(11):2099-2106. PubMed ID: 37592141 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Cantini F; Niccoli L; Nannini C; Kaloudi O; Cassarà E; Susini M; Lenzetti I Biologics; 2012; 6():5-12. PubMed ID: 22291462 [TBL] [Abstract][Full Text] [Related]
13. Uveitis in Behçet disease - an update. Tugal-Tutkun I Curr Opin Rheumatol; 2023 Jan; 35(1):17-24. PubMed ID: 36255985 [TBL] [Abstract][Full Text] [Related]
14. Six-month outcomes of infliximab and tocilizumab therapy in non-infectious retinal vasculitis. Karaca I; Uludag G; Matsumiya W; Regenold J; Or C; Mobasserian A; Halim MS; Zaidi M; Lajevardi S; Dongchau A; Ghoraba H; Nguyen QD Eye (Lond); 2023 Aug; 37(11):2197-2203. PubMed ID: 36443499 [TBL] [Abstract][Full Text] [Related]
15. Long-Term Infliximab Treatment in Psoriasis Patients: A National Multicentre Retrospective Study. Carlet C; Bichard D; Richard MA; Mahé E; Saillard C; Brenaut E; Dupuy A; Misery L; Villani A; Jullien D; Puzenat E; Nardin C; Aubin F; Groupe de Recherche Sur le Psoriasis de la Société Française de Dermatologie Dermatol Res Pract; 2020; 2020():2042636. PubMed ID: 32231699 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN). Cheon JH; Kim HS; Han DS; Kim SK; Shin SJ; Kim JS; Ye BD; Song GA; Lee Y; Kim Y; Lee Y; Kim WH; Gut Liver; 2023 Sep; 17(5):777-785. PubMed ID: 36578194 [TBL] [Abstract][Full Text] [Related]
17. Twenty Years of Quiescence after Nonstop Remicade Evereklioglu C Case Rep Ophthalmol; 2023; 14(1):75-82. PubMed ID: 36843645 [TBL] [Abstract][Full Text] [Related]
18. How challenging can it be to treat Behçet uveitis? Oray M; Cebeci Z; Kir N; Tugal-Tutkun I Saudi J Ophthalmol; 2022; 36(4):397-399. PubMed ID: 36618572 [TBL] [Abstract][Full Text] [Related]
19. Clinical observations on infliximab treatment of infantile onset Takayasu arteritis. Kang M; Lai J; Zhang D; Xu Y; Zhu J; Li M Pediatr Rheumatol Online J; 2022 Aug; 20(1):61. PubMed ID: 35927694 [TBL] [Abstract][Full Text] [Related]
20. Infliximab for parenchymal neuro-Behçet's syndrome: case series and meta-analysis. Wang X; Liu Y; Ao Y; Wang J; Liu J; Xu Y; Zheng W Clin Exp Rheumatol; 2024 May; ():. PubMed ID: 38757293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]